Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

医学 华法林 心房颤动 危险系数 内科学 冲程(发动机) 随机对照试验 依杜沙班 蒂米 比例危险模型 心脏病学
作者
Anthony P. Carnicelli,Hwanhee Hong,Stuart J Connolly,John Eikelboom,Robert P. Giugliano,David A. Morrow,Manesh R. Patel,Lars Wallentin,John H. Alexander,M. Cecilia Bahit,Alexander P. Benz,Erin A. Bohula,Tze-Fan Chao,Leanne Dyal,Michael Ezekowitz,Keith A.A. Fox,Baris Gencer,Jonathan L Halperin,Ziad Hijazi,Stefan H Hohnloser
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:145 (4): 242-255 被引量:313
标识
DOI:10.1161/circulationaha.121.056355
摘要

Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. Methods: We used individual patient data from the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database, which includes all patients randomized in the 4 pivotal trials of DOACs versus warfarin in atrial fibrillation (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), to perform network meta-analyses using a stratified Cox model with random effects comparing standard-dose DOAC, lower-dose DOAC, and warfarin. Hazard ratios (HRs [95% CIs]) were calculated for efficacy and safety outcomes. Covariate-by-treatment interaction was estimated for categorical covariates and for age as a continuous covariate, stratified by sex. Results: A total of 71 683 patients were included (29 362 on standard-dose DOAC, 13 049 on lower-dose DOAC, and 29 272 on warfarin). Compared with warfarin, standard-dose DOACs were associated with a significantly lower hazard of stroke or systemic embolism (883/29 312 [3.01%] versus 1080/29 229 [3.69%]; HR, 0.81 [95% CI, 0.74–0.89]), death (2276/29 312 [7.76%] versus 2460/29 229 [8.42%]; HR, 0.92 [95% CI, 0.87–0.97]), and intracranial bleeding (184/29 270 [0.63%] versus 409/29 187 [1.40%]; HR, 0.45 [95% CI, 0.37–0.56]), but no statistically different hazard of major bleeding (1479/29 270 [5.05%] versus 1733/29 187 [5.94%]; HR, 0.86 [95% CI, 0.74–1.01]), whereas lower-dose DOACs were associated with no statistically different hazard of stroke or systemic embolism (531/13 049 [3.96%] versus 1080/29 229 [3.69%]; HR, 1.06 [95% CI, 0.95–1.19]) but a lower hazard of intracranial bleeding (55/12 985 [0.42%] versus 409/29 187 [1.40%]; HR, 0.28 [95% CI, 0.21–0.37]), death (1082/13 049 [8.29%] versus 2460/29 229 [8.42%]; HR, 0.90 [95% CI, 0.83–0.97]), and major bleeding (564/12 985 [4.34%] versus 1733/29 187 [5.94%]; HR, 0.63 [95% CI, 0.45–0.88]). Treatment effects for standard- and lower-dose DOACs versus warfarin were consistent across age and sex for stroke or systemic embolism and death, whereas standard-dose DOACs were favored in patients with no history of vitamin K antagonist use ( P =0.01) and lower creatinine clearance ( P =0.09). For major bleeding, standard-dose DOACs were favored in patients with lower body weight ( P =0.02). In the continuous covariate analysis, younger patients derived greater benefits from standard-dose (interaction P =0.02) and lower-dose DOACs (interaction P =0.01) versus warfarin. Conclusions: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with atrial fibrillation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
littlewhite完成签到,获得积分10
刚刚
香蕉觅云的应助被端庄沉鱼采纳,获得10
刚刚
低级研究生完成签到 ,获得积分10
刚刚
1秒前
LDJ发布了新的文献求助10
1秒前
咩咩蓝发布了新的文献求助10
1秒前
1秒前
HDT仔仔的应助被lcsw采纳,获得10
1秒前
WanWanYUE完成签到 ,获得积分10
1秒前
Lia发布了新的文献求助10
2秒前
Akim的应助被Chenzr采纳,获得10
2秒前
轻松大王完成签到,获得积分10
2秒前
QQQQ完成签到,获得积分10
2秒前
漂亮的曼文完成签到 ,获得积分10
2秒前
3秒前
斯文败类的应助被颖颖不吃酸采纳,获得10
3秒前
ZjieY完成签到,获得积分10
3秒前
潇洒的鼠标完成签到,获得积分10
3秒前
Elaine完成签到,获得积分10
4秒前
xiaomaihua发布了新的文献求助10
4秒前
166发布了新的文献求助10
4秒前
4秒前
5秒前
6秒前
酷波er的应助被沉静的爆米花采纳,获得10
6秒前
木昆完成签到 ,获得积分10
6秒前
6秒前
脑洞疼的应助被牛123采纳,获得10
6秒前
谨慎元蝶完成签到,获得积分10
6秒前
6秒前
钱罐罐完成签到 ,获得积分10
7秒前
7秒前
粽子完成签到,获得积分10
7秒前
哈基米发布了新的文献求助10
7秒前
7秒前
8秒前
shilimiao完成签到,获得积分10
8秒前
wzx发布了新的文献求助10
8秒前
天天快乐的应助被曾图图采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8167861
求助须知:如何正确求助?哪些是违规求助? 9560824
关于积分的说明 21757886
捐赠科研通 7759010
什么是DOI,文献DOI怎么找? 3429723
关于科研通互助平台的介绍 2553707
邀请新用户注册赠送积分活动 2474336